Christopher Marai
Stock Analyst at Nomura
(2.45)
# 2,356
Out of 4,876 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $7.40 | +12,872.97% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $55.69 | -40.74% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $4.72 | +1,806.78% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $322.83 | -77.08% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $2.96 | +440.54% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $126.08 | +210.91% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $2.45 | +1,287.76% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $17.11 | +1,244.24% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $9.03 | +32.96% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $6.08 | +212.50% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.47 | +2,825.17% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $7.40
Upside: +12,872.97%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $55.69
Upside: -40.74%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $4.72
Upside: +1,806.78%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $322.83
Upside: -77.08%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $2.96
Upside: +440.54%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $126.08
Upside: +210.91%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $2.45
Upside: +1,287.76%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $17.11
Upside: +1,244.24%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $9.03
Upside: +32.96%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $6.08
Upside: +212.50%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.47
Upside: +2,825.17%